Haemonetics Stock Performance
| HAE Stock | USD 80.21 0.31 0.39% |
On a scale of 0 to 100, Haemonetics holds a performance score of 14. The company retains a Market Volatility (i.e., Beta) of -0.0719, which attests to not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Haemonetics are expected to decrease at a much lower rate. During the bear market, Haemonetics is likely to outperform the market. Please check Haemonetics' downside deviation, total risk alpha, value at risk, as well as the relationship between the information ratio and treynor ratio , to make a quick decision on whether Haemonetics' current trending patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Haemonetics are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Haemonetics exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.39 | Five Day Return (4.33) | Year To Date Return 2.31 | Ten Year Return 160 | All Time Return 1.3 K |
Last Split Factor 2:1 | Last Split Date 2012-12-03 |
1 | Haemonetics Fiscal Q2 Earnings Snapshot | 11/06/2025 |
2 | A Piece Of The Puzzle Missing From Haemonetics Corporations 36 percent Share Price Climb | 11/07/2025 |
3 | Why Haemonetics is a Top Momentum Stock for the Long-Term | 11/13/2025 |
4 | Isthmus Partners LLC Raises Stock Holdings in Haemonetics Corporation HAE | 12/02/2025 |
5 | Why Haemonetics is a Top Growth Stock for the Long-Term | 12/03/2025 |
6 | Intuitive Surgical cut as Citi previews 2026 in MedTech | 12/11/2025 |
7 | Is it Apt to Retain Haemonetics Stock in Your Portfolio Now | 12/12/2025 |
8 | Why Haemonetics Shares Are Trading Lower Today | 12/15/2025 |
9 | Riverwater Partners Small Cap Strategy Sold Its Stake in Haemonetics Corporation in Q3 | 12/16/2025 |
10 | Are You a Value Investor This 1 Stock Could Be the Perfect Pick | 12/18/2025 |
| Begin Period Cash Flow | 178.8 M | |
| Total Cashflows From Investing Activities | -161.9 M |
Haemonetics | Build AI portfolio with Haemonetics Stock |
Haemonetics Relative Risk vs. Return Landscape
If you would invest 5,118 in Haemonetics on September 21, 2025 and sell it today you would earn a total of 2,903 from holding Haemonetics or generate 56.72% return on investment over 90 days. Haemonetics is generating 0.7857% of daily returns assuming volatility of 4.388% on return distribution over 90 days investment horizon. In other words, 39% of stocks are less volatile than Haemonetics, and above 85% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Haemonetics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Haemonetics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Haemonetics, and traders can use it to determine the average amount a Haemonetics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1791
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | HAE | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Haemonetics is performing at about 14% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Haemonetics by adding it to a well-diversified portfolio.
Haemonetics Fundamentals Growth
Haemonetics Stock prices reflect investors' perceptions of the future prospects and financial health of Haemonetics, and Haemonetics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Haemonetics Stock performance.
| Return On Equity | 0.19 | ||||
| Return On Asset | 0.0636 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.21 % | ||||
| Current Valuation | 4.67 B | ||||
| Shares Outstanding | 46.81 M | ||||
| Price To Earning | 50.35 X | ||||
| Price To Book | 4.41 X | ||||
| Price To Sales | 2.90 X | ||||
| Revenue | 1.36 B | ||||
| Gross Profit | 790.03 M | ||||
| EBITDA | 355.99 M | ||||
| Net Income | 167.68 M | ||||
| Cash And Equivalents | 306.76 M | ||||
| Cash Per Share | 4.79 X | ||||
| Total Debt | 1.22 B | ||||
| Debt To Equity | 1.12 % | ||||
| Current Ratio | 2.73 X | ||||
| Book Value Per Share | 18.16 X | ||||
| Cash Flow From Operations | 181.72 M | ||||
| Earnings Per Share | 3.42 X | ||||
| Market Capitalization | 3.85 B | ||||
| Total Asset | 2.45 B | ||||
| Retained Earnings | 352.17 M | ||||
| Working Capital | 356.86 M | ||||
| Current Asset | 488.09 M | ||||
| Current Liabilities | 185.55 M | ||||
About Haemonetics Performance
By analyzing Haemonetics' fundamental ratios, stakeholders can gain valuable insights into Haemonetics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Haemonetics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Haemonetics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 217.82 | 187.49 | |
| Return On Tangible Assets | 0.12 | 0.10 | |
| Return On Capital Employed | 0.12 | 0.09 | |
| Return On Assets | 0.07 | 0.05 | |
| Return On Equity | 0.20 | 0.12 |
Things to note about Haemonetics performance evaluation
Checking the ongoing alerts about Haemonetics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Haemonetics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Haemonetics appears to be risky and price may revert if volatility continues | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: Are You a Value Investor This 1 Stock Could Be the Perfect Pick |
- Analyzing Haemonetics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Haemonetics' stock is overvalued or undervalued compared to its peers.
- Examining Haemonetics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Haemonetics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Haemonetics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Haemonetics' stock. These opinions can provide insight into Haemonetics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Haemonetics Stock analysis
When running Haemonetics' price analysis, check to measure Haemonetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Haemonetics is operating at the current time. Most of Haemonetics' value examination focuses on studying past and present price action to predict the probability of Haemonetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Haemonetics' price. Additionally, you may evaluate how the addition of Haemonetics to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |